A current shortage of Adderall is expected to continue at least through the end of 2022, with supply unable to meet the growing demand for the popular medication used in treating ADHD and narcolepsy.
The U.S. Food and Drug Administration confirmed earlier this month what pharmacists, doctors and patients have been saying for months as they scramble to find enough of the product.
“We will continue to monitor supply and assist manufacturers with anything needed to resolve the shortage,” the FDA said in its announcement. “There is not sufficient supply to continue to meet U.S. market demand.”
As an example, the FDA cited Teva Pharmaceutical Industries Ltd. – which sells more Adderall in the U.S. than any other company – and said it was dealing with ongoing intermittent manufacturing delays.
Teva spokesperson Kelley Dougherty said an earlier labor shortage, combined with rising demand and manufacturing limits set by the U.S. Drug Enforcement Administration, all contributed to the shortage.
“We are fully committed to manufacture and distribute as much product as possible each day,” Dougherty told The Wall Street Journal.
Print Page
Email to a Friend